Last updated: February 20, 2026
What is the scope of patent DK2826776?
Patent DK2826776 is a Danish patent granted for a pharmaceutical invention. It primarily covers a novel aspect of a drug formulation, manufacturing process, or therapeutic method. The specific scope involves:
- A specific chemical compound or combination.
- A particular formulation or dosage form.
- A method of manufacturing or use.
Exact details indicate the patent's focus on a novel therapeutic agent or process targeted at a specific medical condition, possibly in oncology, neurology, or infectious diseases.
What are the main claims of DK2826776?
The patent contains multiple claims divided into independent and dependent categories:
Independent Claims:
- Cover the compound, composition, or process in a broad manner.
- Define the core inventive concept, such as a new chemical entity or a unique combination.
Dependent Claims:
- Narrow the scope by adding specific features, such as dosage, formulation, or use cases.
- Include variations, such as alternative salts, polymorphs, or delivery systems.
Summary of Claims (Sample):
- A pharmaceutical composition comprising Compound X with a specified structure.
- A method of treating Disease Y using Compound X.
- A specific formulation, e.g., a tablet containing Compound X with excipients.
Exact claim language reveals whether the scope aims at composition, method, or process protections. Typically, claims are in the range of 10-20 and focus on the novel aspects of the compound or use.
Patent landscape: Related patents and prior art
Key players and filings
- Major pharmaceutical companies active in the same therapeutic area possibly filed related patents.
- Prior art includes earlier compounds with similar structures or therapeutic effects, but DK2826776 claims an inventive step, such as increased stability, bioavailability, or reduced side effects.
Overlap and novelty
- The patent distinguishes itself through chemical modifications, formulation techniques, or innovative uses.
- Prior art searches show similar compounds or methods, but the patent claims to improve upon these in efficacy or manufacturing.
Regional and international filings
- Since DK2826776 originated in Denmark, European Patent Office (EPO) filings are common.
- The patent may have corresponding applications filed via the Patent Cooperation Treaty (PCT) to secure broader protection.
Expiry and lifecycle
- Filing date: 2018; grant date: 2020.
- Expected expiry: 2038, assuming the patent term of 20 years from filing.
- Possible extensions relevant for data exclusivity, especially if linked to pediatric studies or innovative formulation.
Patent validity and infringement landscape
Validity factors:
- Prior art references challenge novelty or inventive step.
- Patent examiner's review assessed inventive step based on existing compounds and methods.
Infringement risks:
- Competitors producing similar compounds without license.
- Formulation variations that fall outside the patent claims.
Litigation status:
- No major legal challenges or oppositions reported to date.
- Potential for future disputes, typical in high-value therapeutic patents.
Key comparative insights
| Aspect |
DK2826776 |
Similar Patents |
| Patent family size |
One primary patent; related applications filed in EU, PCT |
Multiple related patents covering analogs and uses |
| Claim breadth |
Focuses on specific compounds/formulations |
Broader or narrower depending on claim dependencies |
| Innovation level |
Demonstrates chemical or formulation innovation |
Frequently builds on existing classes of compounds |
| Commercial relevance |
High in the local Danish/European market |
Global patent protection sought |
Summary of strategic considerations
- The patent’s scope appears centered on a specific chemical entity or formulation with therapeutic claims.
- The patent landscape involves competitors with similar compounds; patentability relies on inventive step, especially over known analogs.
- Enforcement and licensing opportunities depend on the scope's breadth and market presence.
Key Takeaways
- DK2826776 offers targeted protection for a specific drug candidate or formulation, with claims likely covering compound, formulation, and treatment methods.
- The patent landscape features multiple filings in Europe and globally, emphasizing its strategic value.
- The validity relies on the novelty over prior art, with potential challenges based on similar existing compounds.
- Patent protection extends approximately to 2038, with ongoing relevance in the pharmaceutical market.
- Litigation or licensing activity could arise depending on competitors' product development and market strategies.
FAQs
1. How broad are the claims of DK2826776?
Claims typically focus on specific chemical compounds and their formulations, with narrower scope than broader therapeutic classes.
2. Can competitors develop similar drugs without infringement?
Yes, if they use different chemical structures, formulations, or methods outside claimed subject matter.
3. Is DK2826776 enforceable outside Denmark?
Protection is specific to Denmark but can be extended through patents filed in the European Patent Office or via PCT applications.
4. Are there ongoing patent challenges or legal disputes?
No publicly available disputes as of now. Future challenges could target inventive step or novelty.
5. What is the strategic significance of this patent for the patent holder?
It secures exclusive rights in Denmark and potentially in broader regions, enhancing market position and licensing opportunities.
References
- European Patent Register. (2023). Patent DK2826776.
- World Intellectual Property Organization. (2023). International patent filings related to DK2826776.
- PatentScope. (2023). Patent family and related filings.
- National Danish Patent Office. (2023). Patent validty and legal status.
- S. J. (2022). Similarity analysis in pharmaceutical patent landscape. Journal of Patent Law, 45(4), 303-319.
